Amgen to acquire ChemoCentryx for $52/share in cash at total enterprise value of ~$3.7B representing a premium of ~116% to the last close date. The transaction is expected to close in Q4’22
The acquisition will enable Amgen to add its decades-long leadership in inflammation & nephrology with Tavneos which focused on developing treatments for autoimmune diseases, inflammatory disorders & cancer. ChemoCentryx has 3 early-stage drug products targeting chemoattractant receptors in other inflammatory diseases & oral checkpoint inhibitor for cancer
Tavneos was approved in the US for sev. active ANCA-associated vasculitis in combination with standard therapy & was also approved outside of the US incl. the EU & Japan. Amgen’s portfolio includes Otezla, Enbrel, Tezspire, Amgevita, Riabni & Avsola
Ref: Amgen | Image: Chemocentryx
